SVB Leerink Downgrades Zymeworks (ZYME) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts ZYME Hot Sheet
Price: $24.77 -1.2%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
SVB Leerink analyst Andrew Berens downgraded Zymeworks (NYSE: ZYME) from Outperform to Market Perform with a price target of $41.00.
For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.
Shares of Zymeworks closed at $40.30 yesterday.
You May Also Be Interested In
- BofA Securities Downgrades Albertsons Companies Inc. (ACI) to Underperform
- Huber Research double downgrades Netflix to underweight, sets $70 price target
- Goldman Sachs Downgrades Albertsons Companies Inc. (ACI) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
